NEWS & PERSPECTIVES

Year:

  • All
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020

Type:

  • All
  • Awards
  • Kura Kommentary
  • Life at Kura
  • Media Coverage

EXPERT PERSPECTIVES ON AML AND ZIFTOMENIB CLINICAL TRIALS

Harry Erba, MD, PhD

Dr. Erba offers insight into the KOMET-007 Phase 1 trial and rationale for investigating ziftomenib in combination with standards of care for the treatment of patients with newly diagnosed or R/R NPM1-m or KMT2A-r AML

Amir T. Fathi, MD

Amer Zeidan, MBBS, MHS

MEDIA RESOURCES

Essential assets such as logos and images related to Kura Oncology.